Kazia Therapeutics Limited
KZIA
$13.25
$3.1931.71%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -98.22% | -98.26% | -- | -- | -- |
| Total Other Revenue | 891.58% | 872.76% | -- | -- | 18,900.00% |
| Total Revenue | -29.21% | -30.53% | -- | -- | 272,400.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -29.21% | -30.53% | -- | -- | 272,400.00% |
| SG&A Expenses | -61.03% | -61.76% | 12.13% | 14.74% | 106.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -70.67% | -71.22% | 5.70% | 8.17% | 107.05% |
| Operating Income | 75.93% | 76.38% | -5.45% | -7.91% | -83.78% |
| Income Before Tax | 36.28% | 37.47% | -18.18% | -20.95% | -154.42% |
| Income Tax Expenses | -1,056.50% | -1,035.06% | 0.00% | -2.25% | 1.33% |
| Earnings from Continuing Operations | 44.51% | 45.55% | -18.46% | -21.23% | -157.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 44.51% | 45.55% | -18.46% | -21.23% | -157.48% |
| EBIT | 75.93% | 76.38% | -5.45% | -7.91% | -83.78% |
| EBITDA | 77.15% | 78.38% | -6.09% | -8.57% | -92.09% |
| EPS Basic | 76.21% | 76.66% | 33.19% | 31.63% | -99.58% |
| Normalized Basic EPS | 88.02% | 88.24% | 27.27% | 25.57% | -33.98% |
| EPS Diluted | 76.21% | 76.66% | 33.19% | 31.63% | -99.58% |
| Normalized Diluted EPS | 88.02% | 88.24% | 27.27% | 25.57% | -33.98% |
| Average Basic Shares Outstanding | 133.25% | 133.25% | 77.29% | 77.29% | 29.00% |
| Average Diluted Shares Outstanding | 136.36% | 136.36% | 88.89% | 88.89% | 37.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |